Bioceres Crop Solutions Corp. (NASDAQ: BIOX): Corporate Profile & Financials

By Raveendran R | Updated on: November 15, 2026

Source: Bioceres Crop Solutions Corp. Form 20-F Fiscal Year 2026

Metrics for FY 2026 Ended Jun 30, 2026
Income Statement Metrics
Revenue
$237.84 M (▼ 17.3%)
Prev Year: $287.66 M
Gross Profit
$83.18 M (▼ 20.8%)
Prev Year: $105.04 M
Operating Profit
-$23.41 M (▼ 454.8%)
Prev Year: $6.60 M
Net Profit
-$263.94 M (▼ 348.5%)
Prev Year: -$58.85 M
Gross Margin
34.97 % (▼ 154 bps)
Prev Year: 36.52 %
Operating Margin
-9.84 % (▼ 1214 bps)
Prev Year: 2.29 %
PAT Margin
-110.98 % (▼ 9052 bps)
Prev Year: -20.46 %
ROA
-58.89 % (▼ 5118 bps)
Prev Year: -7.71 %
ROE
-774.98 % (▼ 75505 bps)
Prev Year: -19.93 %
Asset Turnover
0.53x (▲ 0.15 pts)
Prev Year: 0.38x
Balance Sheet Metrics
Total Assets
$448.23 M (▼ 41.3%)
Prev Year: $763.65 M
Current Assets
$215.40 M (▼ 30.1%)
Prev Year: $308.31 M
Total Liabilities
$414.17 M (▼ 11.6%)
Prev Year: $468.43 M
Current Liabilities
$270.33 M (▼ 20.0%)
Prev Year: $337.99 M
Total Debt
$229.20 M (▼ 11.9%)
Prev Year: $260.20 M
Total Equity
$34.06 M (▼ 88.5%)
Prev Year: $295.22 M
Working Capital
-$54.93 M (▼ 85.1%)
Prev Year: -$29.67 M
Current Ratio
0.80x (▼ 0.12 pts)
Prev Year: 0.91x
Debt to Equity
6.73x (▲ 5.85 pts)
Prev Year: 0.88x
Debt to Assets
0.51x (▲ 0.17 pts)
Prev Year: 0.34x
Equity Multiplier
13.16x (▲ 10.57 pts)
Prev Year: 2.59x
Cash Flow Metrics
Operating Cash Flow
$66.01 M (▲ 32.3%)
Prev Year: $49.91 M
CapEx
$3.53 M (▼ 66.5%)
Prev Year: $10.52 M
Free Cash Flow
$62.48 M (▲ 58.6%)
Prev Year: $39.39 M
FCF Margin
26.27 % (▲ 1258 bps)
Prev Year: 13.69 %
Cash ROE
193.82 % (▲ 17691 bps)
Prev Year: 16.90 %
CF to Debt
0.29x (▲ 0.10 pts)
Prev Year: 0.19x

📋 Quick Facts / Company Snapshot

Corporate Snapshot Key Metric Official Disclosed Value
Official Name Bioceres Crop Solutions Corp.
Ticker Symbol BIOX
Primary Exchange Nasdaq Capital Market (Transferred from Nasdaq Global Select Market on September 18, 2026)
Principal Executive Offices Ocampo 210 bis, Predio CCT, Rosario, Province of Santa Fe, Argentina
Industry / Sector Agricultural Biotechnology & Crop Productivity Solutions
Founded 2001 (Bioceres S.A. founded in 2001; Bioceres Crop Solutions Corp. incorporated November 14, 2017)
Total Employees 562 full-time employees (Continuing operations as of June 30, 2026)
Key Operational Locations Rosario (Argentina), Pergamino (Argentina), Londrina (Brazil)
Patents & Intellectual Property Over 180 patents and patent applications; 1,250+ trademarks worldwide
Principal Subsidiaries BCS Holding Inc., Bioceres Crops do Brasil Ltda., Bioceres Crops S.A., Bioceres Semillas S.A.U., Comer. Agrop. Rizobacter de Bolivia S.A., Insumos Agroquímicos S.A., Pro Farm Group, Inc., Rasa Holding LLC, Rizobacter Argentina S.A., Rizobacter Colombia SAS, Rizobacter del Paraguay S.A., Rizobacter do Brasil Ltda., Rizobacter France SAS, Rizobacter South Africa, Rizobacter Uruguay, Rizobacter USA, LLC, Verdeca LLC
Parent Company Bioceres Group Limited (Former parent company; deconsolidated following Bioceres S.A. bankruptcy in March 2026)
Chief Executive Officer Federico Trucco, Ph.D.
Chief Financial Officer Ezequiel Simmermacher
External Website www.biocerescrops.com

🏢 The Corporate Identity: Who They Are & Where They Came From

The Big Picture

Bioceres Crop Solutions Corp. is a fully integrated agricultural biotechnology enterprise focused on developing and commercializing productivity solutions designed to regenerate agricultural ecosystems while enhancing crop resilience to climate change. Operating globally, the group develops climate-smart ag-tech products that incentivize farmers to adopt sustainable production methods without sacrificing economic yields.

The company maintains a broad intellectual property portfolio featuring high-impact, licensed, and patented technologies spanning seeds, microbial ag-inputs, biological crop protection, and next-generation crop nutrition. Its solutions target major agricultural challenges, including drought stress, soil degradation, and pest management, across key commercial row crops such as soybeans, wheat, and corn.

  • Broad Product Portfolio: Owns or licenses over 1,250 registered brands, 600 registered products, and over 180 patents and patent applications globally.
  • Global Reach: Agricultural inputs marketed across more than 45 countries in South America, North America, Europe, Africa, and Asia.
  • Extensive Commercial Access: Direct and indirect access to growers via a commercial sales force of 148 professionals and relationships with over 1,600 dealers and distributors.

The Founders & Their Legacy

Bioceres was originally established in Argentina in 2001 by a group of forward-thinking agricultural producers and agronomists seeking to address the growing demand for higher crop yields through sustainable, science-based practices. The founders included prominent farm operators, processors, distributors, and early leaders of the sustainable agriculture movement in Latin America, notably founding members of the Argentine Association of Direct Seeding Producers (AAPRESID) and regional consortia members (AACREA).

This producer-led heritage created an open-architecture development model that directly connects scientific discovery with real-world farming applications. This historical origin provided Bioceres with immediate access to a built-in network of early-adopter farmers who served as a validation testing ground for newly commercialized seed traits and microbial solutions.

The Journey: History & Evolution

Over two decades, Bioceres evolved from an Argentine agricultural research network into a publicly traded global biotech platform through targeted acquisitions, research joint ventures, and international commercial partnerships.

In October 2016, the company made a transformative move by acquiring a controlling 50.01% equity stake in Rizobacter Argentina S.A., a global pioneer in liquid inoculants, high-tech adjuvants, and specialty fertilizers with a history spanning over 45 years. Bioceres subsequently expanded its ownership in Rizobacter to 80% in March 2019.

  • Public Listing via Business Combination (2019): Completed a business combination with Union Acquisition Corp. on March 14, 2019, listing its ordinary shares on the NYSE American under the ticker symbol BIOX, and later transferring its listing to The Nasdaq Stock Market in April 2021.
  • Full Ownership of Verdeca (2020): Acquired the remaining 50% interest in Verdeca LLC from Arcadia Biosciences in November 2020, gaining full control over the HB4 soybean trait library and exclusive Latin American rights to Arcadia’s quality wheat traits.
  • Pro Farm Merger & Strategic Pivot (2022–2026): Merged with Pro Farm Group, Inc. (formerly Marrone Bio Innovations) in July 2022 to strengthen its biological crop protection portfolio. Following a 2025 default acceleration on its Secured Notes, the collateral pledged by Pro Farm was subject to a judicial foreclosure auction in January 2026, leading to the reclassification of Pro Farm as a discontinued operation.
  • Syngenta Global Distribution Deal (2022–2026): Executed a 10-year exclusive global distribution agreement with Syngenta Crop Protection in September 2022 for biological seed care solutions, receiving a $50 million upfront license payment, which was subsequently amended in January 2026 to refine commercial targets and distribution scope.

The Corporate Umbrella

Bioceres Crop Solutions Corp. is an exempted company incorporated under the laws of the Cayman Islands on November 14, 2017. The group functions as a holding company operating through direct and indirect operating subsidiaries located across Argentina, Brazil, the United States, Uruguay, Paraguay, Bolivia, Colombia, France, and South Africa.

Historical corporate structures linked Bioceres Crop Solutions to Bioceres S.A. and Bioceres Group Limited. In March 2026, Bioceres S.A. entered judicial bankruptcy proceedings in Argentina, resulting in the loss of control and deconsolidation of Bioceres S.A. and Bioceres LLC by Bioceres Group Limited, shifting the governance dynamic of historical parent entities.

⚙️ The Business Engine: What They Do & Where They Operate

The Core Divisions

The company conducts its continuing business operations through three primary reportable business segments: Crop Protection, Seed & Integrated Products, and Crop Nutrition. Each division targets distinct aspects of the crop production lifecycle, combining biological tools, chemical formulations, and seed technologies.

Business Segment Key Product Lines Fiscal Year 2026 Revenue (in $ millions) Fiscal Year 2026 Gross Margin (%)
Crop Protection Adjuvants, biopesticides, biofungicides, bionematicides, pest control molecules 123.7 34%
Seed & Integrated Products HB4 drought-tolerant seed traits, elite germplasm, custom seed treatment packs 37.7 46%
Crop Nutrition Micro-beaded starter fertilizers, nitrogen-fixing liquid inoculants, biofertilizers, biostimulants 77.0 31%

The Global Product Catalog

Bioceres offers an extensive portfolio of sustainable agricultural solutions designed to maximize crop yield potential while reducing environmental impact:

  • HB4 Drought Tolerance Technology: A patented plant biotechnology trait derived from sunflower genetics that confers tolerance to abiotic stresses, particularly drought and salinity. HB4 increases soybean and wheat yields by an average of 10% to 20% under water-stressed conditions without incurring a yield penalty under optimal growing environments.
  • Microgranular Starter Fertilizers (Microstar): Formulated micro-beaded fertilizers applied directly alongside seeds at planting. Microstar provides immediate availability of essential nutrients like nitrogen, phosphorus, sulfur, and zinc at reduced application rates (20 to 30 kg/ha replacing 80 kg/ha of conventional fertilizers).
  • Biological Seed Inoculants: Liquid inoculants containing nitrogen-fixing bacteria (such as Bradyrhizobium) for leguminous crops like soybeans. Includes Ultra High Concentrate (UHC) and Extended Shelf Life formulations for professional seed treatment.
  • High-Tech Adjuvants: Specialized tank-mix additives that optimize spraying performance, enhance active ingredient absorption, reduce chemical application doses, and limit environmental runoff.
  • Biocontrol & Biofungicides: Microbial pest control solutions including Rizoderma, a biofungicide based on Trichoderma strains for seed and soilborne disease control.

The Names You Know

The group markets its technology catalog through several proprietary brands and trademarked product families:

  • HB4®: The signature drought and stress-tolerance technology platform for wheat and soybeans.
  • Rizobacter®: The global brand identity for biological seed treatment, inoculants, and crop protection products.
  • Microstar PZ® & CMB Bio®: Premium micro-beaded fertilizer lines combining chemical nutrients with beneficial bacterial inoculants.
  • Rizoderma®: Proprietary biological fungicide formulation for seed treatment.
  • Bioceres Semillas®: The internal seed distribution brand used in South America.

Mapping the Global Reach

Bioceres generates the majority of its revenues from agricultural markets in Latin America, while expanding its footprint across North America, Europe, and southern Africa. South America—specifically Argentina—represents the primary commercial hub.

Geographic Region (in $ actual) Fiscal Year 2026 Revenue Fiscal Year 2025 Revenue Fiscal Year 2024 Revenue Latest YoY (%)
Argentina 200,549,303 232,034,876 351,778,631 -13.57%
Brazil 9,917,166 14,861,671 13,671,110 -33.27%
LATAM (Excl. Argentina & Brazil) 14,840,808 18,581,425 21,590,901 -20.13%
Rest of the World (ROW) 12,528,048 22,183,085 33,397,897 -43.52%
Total Consolidated Revenues 237,835,325 287,661,057 420,438,539 -17.32%

The Brick & Mortar Footprint

Bioceres operates manufacturing, research, and logistics assets concentrated in South America, designed with a light fixed-asset structure that offers spare capacity for global scaling:

  • Pergamino Manufacturing Complex (Argentina): The primary operational hub featuring an adjuvant plant (2.1 million gallons annual capacity), two biological production plants (combined 1.87 million gallons capacity), a fungicide/insecticide formulation facility (1.0 million gallons capacity), a micro-beaded fertilizer plant operated via Synertech (50,000 tons capacity), and over 375,000 square feet of warehousing space.
  • Londrina Adjuvant Plant (Brazil): A high-tech adjuvant manufacturing facility completed in Paraná, Brazil, boasting an annual production capacity of approximately 2.6 million gallons to service the Brazilian market.
  • Research & Development Facilities: Primary research laboratories and field testing stations located in Pergamino and Rosario, Argentina, equipped for microbiology, bioprocess scaling, chemistry, and seed breeding.

📊 The Financial Health: The Global Numbers Simplified

Earnings, Expenses, & Take-Home Profits

The following table sets forth the full formal Consolidated Statements of Comprehensive Income of Bioceres Crop Solutions Corp. for the fiscal years ended June 30, 2026, 2025, and 2024, presenting continuing operations separately from discontinued operations.

Consolidated Statement of Comprehensive Income (in $ actual) Fiscal Year 2026 Fiscal Year 2025 Fiscal Year 2024 Latest YoY (%)
Revenues from contracts with customers 237,835,325 287,661,057 420,438,539 -17.32%
Initial recognition and changes in the fair value of biological assets at the point of harvest 441,141 1,764,863 (45,746) -75.00%
Cost of sales (155,095,436) (184,384,992) (263,035,619) -15.89%
Changes in the net realizable value of agricultural products after harvest (346,277) (1,540,776) (2,385,069) -77.53%
Research and development expenses (11,033,441) (9,455,598) (8,372,532) +16.69%
Selling, general and administrative expenses (71,227,886) (93,701,345) (96,974,913) -23.98%
Share of profit or loss of joint ventures and associates 216,110 (1,126,312) 4,049,508 N/M
Other income or expenses, net (24,198,391) 7,380,799 (1,539,458) N/M
Operating (loss) / profit (23,408,855) 6,597,696 52,134,710 N/M
Financial cost (39,923,224) (25,078,507) (24,809,708) +59.19%
Other financial results (12,148,207) (28,036,711) (5,069,215) -56.67%
(Loss) / Profit before income tax (75,480,286) (46,517,522) 22,255,787 +62.26%
Income tax (6,957,743) (2,618,488) (6,603,649) +165.72%
(Loss) / Profit of the year from continuing operations (82,438,029) (49,136,010) 15,652,138 +67.78%
Discontinued operations (199,719) (9,709,243) (8,363,155) -97.94%
Loss related to foreclosure (181,305,248) 0 0 N/M
Loss of the year from discontinued operations (181,504,967) (9,709,243) (8,363,155) +1769.40%
(Loss) / Profit of the year (263,942,996) (58,845,253) 7,288,983 +348.54%
Total Comprehensive (Loss) / Profit (261,419,839) (59,559,504) 6,501,629 +338.92%

Assets, Debts, & Corporate Wealth

The following table sets forth the full formal Consolidated Statements of Financial Position of Bioceres Crop Solutions Corp. as of June 30, 2026, and June 30, 2025.

Consolidated Statement of Financial Position (in $ actual) As of June 30, 2026 As of June 30, 2025 Latest YoY (%)
Cash and cash equivalents 11,242,958 32,695,079 -65.61%
Other financial assets (Current) 1,001,241 2,040,038 -50.92%
Trade receivables (Current) 98,211,154 165,859,933 -40.79%
Other receivables (Current) 12,060,759 15,861,981 -23.96%
Recoverable income tax (Current) 1,445,908 1,864,817 -22.46%
Inventories 46,408,777 87,611,269 -47.03%
Biological assets 594,543 2,378,380 -75.00%
Assets subject to foreclosure 44,430,378 0 N/M
Total Current Assets 215,395,718 308,311,497 -30.14%
Other financial assets (Non-current) 0 58 -100.00%
Trade receivables (Non-current) 731,919 2,506,834 -70.80%
Other receivables (Non-current) 16,228,480 23,660,530 -31.41%
Recoverable income tax (Non-current) 0 17,995 -100.00%
Deferred tax assets 274,314 4,916,980 -94.42%
Investments in joint ventures and associates 40,780,055 39,371,264 +3.58%
Investment properties 0 570,324 -100.00%
Property, plant and equipment 60,655,861 74,575,386 -18.67%
Intangible assets 74,655,056 181,173,079 -58.79%
Goodwill 28,550,361 112,163,432 -74.55%
Right of use asset 10,956,448 16,377,701 -33.10%
Total Assets 448,228,212 763,645,080 -41.30%
Trade and other payables (Current) 57,674,444 96,432,604 -40.19%
Borrowings (Current) 47,260,267 119,728,126 -60.53%
Employee benefits and social security (Current) 4,846,155 6,174,012 -21.51%
Deferred revenue and advances from customers (Current) 2,140,338 4,282,668 -50.02%
Income tax payable 4,866,139 452,800 +974.68%
Consideration for acquisition (Current) 42,564 1,761,274 -97.58%
Secured notes (Current) 121,956,575 102,270,445 +19.25%
Lease liabilities (Current) 2,108,964 6,884,042 -69.36%
Liabilities subject to foreclosure 29,430,378 0 N/M
Total Current Liabilities 270,325,824 337,985,971 -20.02%
Trade and other payables (Non-current) 41,956,936 48,481,726 -13.46%
Borrowings (Non-current) 59,982,642 38,198,026 +57.03%
Deferred revenue and advances from customers (Non-current) 1,436,912 1,436,912 0.00%
Joint ventures and associates (Non-current liability) 1,092,995 1,007,678 +8.47%
Deferred tax liabilities 23,907,907 30,122,920 -20.63%
Provisions 6,325,454 1,267,572 +399.02%
Consideration for acquisition (Non-current) 359,846 397,774 -9.54%
Lease liabilities (Non-current) 8,781,609 9,527,939 -7.83%
Total Liabilities 414,170,125 468,426,518 -11.58%
Total Equity 34,058,087 295,218,562 -88.46%

Cash Flow: Tracking the Money Movement

The following table sets forth the full formal Consolidated Statements of Cash Flows of Bioceres Crop Solutions Corp. for the fiscal years ended June 30, 2026, 2025, and 2024.

Consolidated Statement of Cash Flows (in $ actual) Fiscal Year 2026 Fiscal Year 2025 Fiscal Year 2024 Latest YoY (%)
Loss of the year (263,942,996) (58,845,253) 7,288,983 +348.54%
Loss of the year from discontinued operations 181,504,967 9,709,243 8,363,155 +1769.40%
Income tax 6,957,743 2,618,488 6,603,649 +165.72%
Financial results 52,071,431 53,115,218 29,878,923 -1.97%
Depreciation of property, plant and equipment 5,908,863 4,724,278 4,481,546 +25.07%
Amortization of intangible assets 6,543,341 6,113,503 4,978,718 +7.03%
Depreciation of leased assets 3,334,114 4,313,516 2,337,840 -22.71%
Other contingencies 3,499,866 0 0 N/M
Impairment of intangible assets and goodwill 15,584,021 0 0 N/M
Impairment of other receivables from joint ventures and associates 7,667,621 0 0 N/M
Other restructuring and transaction-related expenses and charges 6,242,915 3,445,247 87,198 +81.20%
Share-based incentive and stock options 164,030 3,702,351 12,787,122 -95.57%
Share of profit or loss of joint ventures and associates (216,110) 1,126,312 (4,049,508) N/M
Provisions for contingencies 2,401,951 335,773 367,126 +615.35%
Allowance for impairment of trade debtors 5,630,839 7,032,818 753,428 -19.93%
Allowance for obsolescence 1,967,300 1,547,723 586,515 +27.11%
Initial recognition and changes in the fair value of biological assets (441,141) (1,764,863) 45,746 -75.00%
Changes in the net realizable value of agricultural products after harvest 346,277 1,540,776 2,385,069 -77.53%
Gain on sale of equipment and intangible assets 0 (7,751,311) (125,464) -100.00%
Trade receivables (Working capital) 51,097,375 23,764,716 (40,786,580) +115.01%
Other receivables (Working capital) 8,574,580 (916,362) (4,967,150) N/M
Income and minimum presumed income taxes (Working capital) (3,366,121) (6,997,089) 4,782,508 -51.89%
Inventories and biological assets (Working capital) 27,437,305 36,367,436 15,023,507 -24.56%
Trade and other payables (Working capital) (39,080,791) (40,860,354) 1,270,082 -4.36%
Employee benefits and social security (Working capital) (917,004) (1,166,946) (2,289,095) -21.42%
Deferred revenue and advances from customers (Working capital) (1,758,908) (128,698) (21,087,704) +1266.69%
Income taxes paid (342,697) 0 (853,299) N/M
Interest collected 248,805 120,568 2,747,398 +106.36%
Inflation effects on working capital adjustments 44,660 139,914 321,103 -68.08%
Net cash flows generated by operating activities from continuing operations 77,162,236 41,287,004 30,930,816 +86.89%
Net cash flows (used in)/generated by operating activities from discontinued operations (11,151,173) 8,618,607 10,785,770 N/M
Net cash flows generated by operating activities 66,011,063 49,905,611 41,716,586 +32.27%
Proceeds from sale of property, plant and equipment 139,923 390,381 336,726 -64.16%
Net cash received from business combination 0 0 37,508 N/M
Net cash outflow from deconsolidation of subsidiary (25,287) 0 0 N/M
Proceeds from financial assets 737,658 19,270,288 888,140 -96.17%
Investment in financial assets (1,021,273) (11,182,107) (7,208,218) -90.87%
Purchase of property, plant and equipment (1,053,612) (5,178,951) (8,492,554) -79.66%
Capitalized development expenditures (2,474,879) (5,339,782) (7,094,693) -53.65%
Purchase of intangible assets (89,769) (350,843) (1,137,071) -74.41%
Net cash flows used in investing activities from continuing operations (3,787,239) (2,391,014) (22,670,162) +58.39%
Net cash flows used in investing activities from discontinued operations (2,076,440) (3,737,877) (6,058,093) -44.45%
Net cash flows used in investing activities (5,863,679) (6,128,891) (28,728,255) -4.33%
Proceeds from borrowings 88,386,288 266,390,032 135,818,247 -66.82%
Repayment of borrowings and financed payments (148,244,840) (291,324,731) (112,614,437) -49.11%
Interest payments (13,406,328) (18,165,853) (24,575,170) -26.20%
Other financial payments (4,523,759) (3,208,933) (2,746,945) +40.97%
Purchase of own shares 0 (926,899) (734,388) -100.00%
Sales of own shares 488,293 0 0 N/M
Leased assets payments (4,289,095) (5,405,955) (3,314,216) -20.66%
Cash dividend distributed by subsidiary 0 (72,051) (174,800) -100.00%
Net cash flows used in financing activities from continuing operations (81,589,441) (52,714,390) (8,341,709) +54.78%
Net cash flows (used in)/generated by financing activities from discontinued operations 2,879,907 2,008,287 (1,714,158) +43.40%
Net cash flows used in financing activities (78,709,534) (50,706,103) (10,055,867) +55.23%
Net decrease in cash and cash equivalents from continuing operations (8,214,444) (13,818,400) (81,055) -40.55%
Net (decrease) / increase in cash and cash equivalents from discontinued operations (10,347,706) 6,889,017 3,013,519 N/M
Net (decrease) / increase in cash and cash equivalents (18,562,150) (6,929,383) 2,932,464 +167.88%
Inflation effects on cash and cash equivalents (321) 2,557 (31,918) N/M
Cash and cash equivalents as of beginning of the year 32,695,079 44,473,270 48,129,194 -26.48%
Effect of exchange rate changes on cash and equivalents (2,333,822) (4,851,365) (6,556,470) -51.89%
Cash reclassified to assets subject to foreclosure (555,828) 0 0 N/M
Cash and cash equivalents as of the end of the year 11,242,958 32,695,079 44,473,270 -65.61%

Funding the Future: R&D and Expansion Spending

Research and development represents the primary innovation engine for Bioceres. The group executes R&D activities through internal discovery teams and strategic collaborations with external academic institutions and public entities.

For the fiscal year ended June 30, 2026, total R&D spending amounted to $14,435,179, comprising $11,033,441 in expensed research costs and $3,401,738 in capitalized development expenditures. This compares to total R&D spending of $18,070,046 in fiscal year 2025 ($9,455,598 expensed and $8,614,448 capitalized) and $20,228,298 in fiscal year 2024 ($8,372,532 expensed and $11,855,766 capitalized).

  • Active Pipeline Projects: As of June 30, 2026, the company maintained 23 active research and development projects covering seed traits, biological crop protection, adjuvants, biostimulants, and formulation platforms.
  • Capital Expenditures (Capex): Outflows for property, plant, and equipment purchases were $1,053,612 in fiscal year 2026, down from $5,178,951 in fiscal year 2025 and $8,492,554 in fiscal year 2024, reflecting a disciplined capital allocation strategy focused on operational consolidation.

🗺️ The Corporate Family Tree: Structure & Investments

Subsidiaries, Associates, & Shared Ventures

Bioceres operates through a network of legal entities across key global agricultural jurisdictions. The table below outlines the principal subsidiaries and joint ventures held directly or indirectly by Bioceres Crop Solutions Corp. as of June 30, 2026:

Subsidiary / Joint Venture Name Jurisdiction of Incorporation Direct/Indirect Ownership Interest (%) Voting Interest (%)
BCS Holding Inc. United States 100% 100%
Bioceres Crops do Brasil Ltda. Brazil 100% 100%
Bioceres Crops S.A. Argentina 90% 90%
Bioceres Semillas S.A.U. Argentina 80% 80%
Comer. Agrop. Rizobacter de Bolivia S.A. Bolivia 80% 80%
Insumos Agroquímicos S.A. Argentina 61% 61%
Natal Agro S.R.L. (Associate) Argentina 31% 31%
Pro Farm Group, Inc. United States 100% 100%
Rasa Holding LLC United States 100% 100%
Rizobacter Argentina S.A. Argentina 80% 80%
Rizobacter Colombia SAS Colombia 80% 80%
Rizobacter del Paraguay S.A. Paraguay 80% 80%
Rizobacter do Brasil Ltda. Brazil 80% 80%
Rizobacter France SAS France 80% 80%
Rizobacter South Africa South Africa 76% 76%
Rizobacter Uruguay Uruguay 80% 80%
Rizobacter USA, LLC United States 80% 80%
Synertech Industrias S.A. (Joint Venture) Argentina 40% 40%
Trigall Genetics S.A. (Joint Venture) Uruguay 50% 50%
Verdeca LLC United States 100% 100%

Strategic Investments & Minority Stakes

The company maintains joint ventures and strategic investments to access external innovation and co-develop specialty formulations:

  • Synertech Industrias S.A.: A 50/50 joint venture between Rizobacter and De Sangosse (resulting in a 40% indirect Group interest) operating a micro-beaded fertilizer plant in Pergamino, Argentina.
  • Trigall Genetics S.A.: A 50/50 joint venture with French wheat breeder Florimond Desprez focused on deregulating and commercializing GM wheat varieties featuring the HB4 trait across South America.
  • Moolec Science SA Holding: The Group holds convertible notes and shares in Moolec Science SA. Following financial distress, Moolec’s shareholders approved a voluntary winding-up in October 2026. As of June 30, 2026, the Group recognized an expected credit loss allowance of $7.7 million against related receivables.
  • Natal Agro S.R.L.: In February 2026, Bioceres disposed of a 20% equity stake in Natal Agro S.R.L., reducing its ownership from 51% to 31%, resulting in a loss of control and shifting the investment to equity-method accounting.

👥 Power & Control: Who Pulls the Strings?

The Brain Trust: Board of Directors & Executive Leadership

The company’s leadership team and board of directors guide its strategic initiatives, research priorities, and financial restructurings:

  • Federico Trucco, Ph.D. (Chief Executive Officer and Executive Director): Age 49. Served as CEO of Bioceres S.A. from 2011 to 2019 and as CEO of Bioceres Crop Solutions Corp. since its public listing in 2019. Holds a Ph.D. in crop sciences and a CBA from the University of Illinois, a Master’s degree in plant pathology from Colorado State University, and a Bachelor’s degree in biochemistry from Louisiana State University.
  • Ezequiel Simmermacher (Chief Financial Officer): Age 40. Appointed CFO on January 5, 2026. Previously served as Director of Operational Excellence & Business Development for South America at CHS Inc. and Regional Finance Director for South America at CHS Inc. Holds an Executive MBA from IAE Business School and an Industrial Engineering degree from ITBA.
  • Yogesh Mago (Non-Executive Director): Age 45. Director since July 12, 2022. Senior Advisor for Ospraie Ag Science LLC since 2016, with over 15 years of investment experience across agriculture, travel, and industrial sectors. Holds a Bachelor’s degree in Finance and International Business from New York University.
  • Antonio Simon Vumbaca (Non-Executive Director): Age 55. Director since November 5, 2025. Specializes in cross-border structuring, crisis arbitration, and governance. Serves as Chair of AIG’s Board and non-executive director of Elemental Altus.
  • Duraiswami (“D”) Narain (Non-Executive Director): Age 63. Director since December 29, 2025. Served as CEO and Managing Director of Bayer CropScience Limited in India from 2018 to 2023, and previously as Global Treasurer and CEO of India operations for Monsanto Company. Chartered accountant holding an MBA from the Kellogg School of Management.

Who Owns the Stock?

As of October 31, 2026, the company had 63,815,891 ordinary shares issued and outstanding. The table below sets forth beneficial ownership for major shareholders holding 5% or more of the outstanding stock:

Beneficial Owner Number of Ordinary Shares Beneficially Owned Percentage of Total Outstanding Stock (%)
Jasper Lake Ventures One LLC 8,710,707 13.6%
Bioceres LLC 6,221,079 9.8%
Ospraie Management LLC 6,233,590 9.8%
Solel Partners LP 4,579,364 7.2%
Agriculture Investment Group Corp. 3,722,732 5.8%

🎯 The Strategic Outlook: Future Plans & Potential Pitfalls

Competitive Advantages & Economic Moats

Bioceres maintains several distinct structural advantages within the agricultural input and biotech markets:

  • First-Mover Trait Advantage: HB4 is the world’s first and only commercially approved drought-tolerant trait technology in wheat, and the first approved Latin American biotech event in major global crops.
  • Global Biological Leadership: Holds an estimated 23% global market share in biological soybean inoculants via Rizobacter, providing an established international brand identity.
  • Capital-Efficient R&D Architecture: Employs open-architecture co-development partnerships with research institutes, reducing early-stage technology discovery costs.
  • Established Distribution Networks: Commercial relationships with over 1,600 dealers and corporate partnership distribution agreements with major agricultural multinationals, including Syngenta.

What Could Go Wrong? Key Challenges & Business Risks

The group faces significant operational, financial, and regulatory risks disclosed in its annual filing:

  • Substantial Doubt About Going Concern: The Group faces severe liquidity constraints, a working capital deficit of $54.9 million as of June 30, 2026, and upcoming short-term debt maturities, generating substantial doubt regarding its ability to continue as a going concern.
  • Ongoing Secured Note Litigation & Judgment: Following a default acceleration in November 2025, noteholders obtained a court judgment of approximately $110.1 million against Bioceres and its guarantors in September 2026, which is currently under appeal.
  • Nasdaq Delisting Risk: Received a deficiency letter from Nasdaq on March 16, 2026, due to trading below the $1.00 minimum bid price, subsequently transferring to the Nasdaq Capital Market with an extension through March 15, 2027 to regain compliance.
  • Latin American Macroeconomic Volatility: Heavy operational concentration in Argentina exposes the group to currency devaluations, foreign exchange access controls, export duties, and regional economic uncertainty.
  • Rizobacter Share Injunction: An ongoing legal dispute dating back to a 1995 share transfer affects 44% of Rizobacter’s capital stock, including shares held by Rasa Holding, exposing the company to contingent obligations for which a $3.5 million provision has been recorded.

The Next Chapter: Growth & Expansion Initiatives

To navigate liquidity challenges and position its product portfolio for long-term growth, management is executing several strategic initiatives:

  • Pivot to HB4 Trait Licensing: Restructuring the HB4 seed business away from direct seed production toward a light-capital trait licensing model, partnering with leading breeders such as Grupo Don Mario (GDM) and the Colorado Wheat Research Foundation (CWRF).
  • Biologicals Capacity Utilization: Scaling production across recently expanded facilities in Pergamino (biologicals) and Londrina (adjuvants) to meet international demand under the Syngenta agreement.
  • Liability Management & Debt Refinancing: Restructuring short-term bank borrowings, having successfully refinanced $74.3 million of local financial debt at Rizobacter to extend maturities through 2028 and 2029.

The Verdict: Strategic Outlook & Conclusion

Bioceres Crop Solutions stands at a critical strategic junction. The company possesses an innovative agricultural biotechnology platform anchored by proprietary biological inoculants, high-performance adjuvants, and groundbreaking drought-tolerant HB4 trait technologies. However, near-term operational success depends directly on resolving its debt obligations, navigating the Secured Note litigation judgment, executing its pivot to a capital-light trait licensing model, and stabilizing its capital structure across South American operating units.

Official Site: www.biocerescrops.com

Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.